|1.||Iwakura, Yoichiro: 84 articles (01/2015 - 09/2002)|
|2.||Kolls, Jay K: 61 articles (10/2015 - 01/2003)|
|3.||Gaffen, Sarah L: 36 articles (10/2015 - 01/2004)|
|4.||Dong, Chen: 31 articles (10/2015 - 03/2003)|
|5.||Miossec, Pierre: 25 articles (01/2015 - 03/2003)|
|6.||van den Berg, Wim B: 24 articles (01/2015 - 03/2003)|
|7.||Li, Xiaoxia: 23 articles (12/2015 - 03/2007)|
|8.||Lubberts, Erik: 22 articles (07/2015 - 03/2003)|
|9.||Nakae, Susumu: 21 articles (02/2015 - 09/2002)|
|10.||Joosten, Leo A B: 21 articles (08/2014 - 03/2003)|
12/01/2014 - "Our results suggest that profound deficiency of IL-17 production associated with a marked decrease in Th17 cells likely contributes significantly to the increased susceptibility of human neonates to invasive bacterial and fungal infections."
01/01/2013 - "Th17 and IL-17 play important roles in the clearance of extracellular bacterial and fungal infections. "
01/01/2012 - "Murine genital tract infection with Neisseria gonorrhoeae has previously been found to induce IL-17 which is important in both recruitment of neutrophils and prompt clearance of the infection. "
02/01/2011 - "Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase."
01/01/2012 - "Protection against H5N1 virus infection was obtained by adoptively transferring PZQ-primed wild type CD8(+) T cells and this was more effective than transfer of activated IFN-γ KO or IL-17 KO CD8(+) T cells. "
04/15/2010 - "Therefore, preventing neutrophil recruitment by blocking the action of IL-17 on endothelial cells may prove to be highly beneficial in diseases in which neutrophilic inflammation plays a key role."
01/01/2015 - "Targeting both IFN-γ and IL-17 may be beneficial for treating the LG inflammation in SS."
12/01/2013 - "Similar to IL-17 or IL-23/p19 depletion, injection of diseased CD18(hypo) PL/J mice with anti-γδTCR Abs significantly reduced skin inflammation and largely eliminated pathological γδ and CD4(+) T cells. "
06/01/2012 - "IL-17 neutralization significantly ameliorates hepatic granulomatous inflammation and liver damage in Schistosoma japonicum infected mice."
09/01/2006 - "Moreover, significantly elevated in vitro production of IL-17, but not of IFN-gamma, correlated with the high pathology, and neutralization of IL-17 in vivo resulted in a significant reduction of hepatic inflammation. "
|3.||Psoriasis (Pustulosis Palmaris et Plantaris)
08/01/2013 - "However, Phase II results of IL-17 blockade with each of these agents has shown a marked improvement of disease severity, thus confirming the pathogenic relevance of IL-17 in mediating crucial inflammatory circuits in psoriasis. "
11/01/2014 - "This recent paradigm shift provides a plausible explanation for the rapid and strong efficacy of the novel compounds targeting IL-17 functions in psoriasis and other inflammatory disorders, and provide a more comprehensive view on the complex cytokine network in these conditions. "
07/24/2014 - "Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. "
03/01/2015 - "These encouraging results demonstrate the efficacy of these agents and validate the pro-inflammatory role of IL-17 in the pathophysiology of psoriasis."
10/27/2015 - "Thus, targeting IκBζ could be a future strategy for treatment of psoriasis, and other inflammatory diseases for which IL-17 antagonists are currently tested in clinical trials. "
10/01/2013 - "The DDX3X-primed CD4(+) T cells produced CD133(+) tumor-specific IFNγ and IL-17 and mediated potent antitumor therapeutic efficacy. "
01/01/2013 - "Consequently, depending on the effector or regulatory role of dendritic cells, blocking IL-17A, may be either dangerous or beneficial for cancer outcomes, thus contributing to the apparent controversy around the role of IL-17A in cancer."
07/01/2010 - "IL-17(-/-) mice exhibited a significant reduction of tumor growth, concomitantly with the decrease of vascular density at lesion area, indicating a pro-tumor property of IL-17. "
01/01/2013 - "In conclusion, blockade of IL-17A at tumor sites helped suppress tumor growth by inhibiting angiogenesis as well as cytotoxic T lymphocytes activation at tumor sites."
01/01/2013 - "Suppression of IL-17A at tumor sites led to a Th1-dominant environment, and moreover, eliminated myeloid-derived suppressor cells and regulatory T cells at tumor sites but not in splenocytes. "
01/01/2015 - "Therapeutic efficacy of IL-17A antibody injection in preventing the development of colitis associated carcinogenesis in mice."
01/01/2014 - "These results demonstrate that IL-17 confers protection against the development of severe colitis through the induction of an atypical M2-like macrophage subpopulation. "
01/01/2014 - "In the present study, by using IL-17 knockout (KO) mice, we investigated the role of IL-17 in colitis, with special focus on the macrophage subpopulations. "
01/01/2015 - "Our findings indicate that BTLA may be involved in the control of inflammatory responses through increasing Foxp3 expression, rather than attenuating IL-17 production, in DSS-induced colitis. "
01/01/2015 - "In a murine T cell transfer model of colitis, transfer of Tpl2-/- T cells resulted in reduced proportions of CD4 T cells expressing IFNγ, but not IL-17A, compared to that induced by wild type T cells. "
|1.||Interleukin-17 (Interleukin 27)
|3.||Interleukin-23 (Interleukin 23)
|5.||Interleukin-6 (Interleukin 6)
|6.||Interferon-gamma (Interferon, gamma)
|7.||Interleukin-10 (Interleukin 10)
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Interleukin-4 (Interleukin 4)
|3.||Drug Therapy (Chemotherapy)